First PREMIER Bank’s CRISPR Therapeutics CRSP Stock Holding History

First PREMIER Bank’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500	Closed	-$23K	–	375
2023 Q3	$23K	Hold	500	–	–	0.01%	251
2023 Q2	$28K	Hold	500	–	–	0.01%	262
2023 Q1	$23K	Hold	500	–	–	0.01%	297
2022 Q4	$20K	Hold	500	–	–	0.01%	298
2022 Q3	$33K	Hold	500	–	–	0.01%	250
2022 Q2	$30K	Hold	500	–	–	0.01%	274
2022 Q1	$31K	Buy	+500	New	+$31.4K	0.01%	262

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

First PREMIER Bank's CRSP Position: Q4 2023 in Review

First PREMIER Bank sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 500 shares — an estimated $23K sold.

First PREMIER Bank first reported a position in CRSP in Q1 2022 and held it in 7 quarters. The position peaked at $33K in Q3 2022. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

First PREMIER Bank reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
First PREMIER Bank sold 500 CRISPR Therapeutics shares in Q4 2023, an estimated $23K.
First PREMIER Bank first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 7 quarters.
First PREMIER Bank's CRISPR Therapeutics position peaked at $33K in Q3 2022.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on First PREMIER Bank's 13F filing for Q4 2023, filed 17 Jan 2024.